Profile data is unavailable for this security.
About the company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
- Revenue in CHF (TTM)5.85bn
- Net income in CHF909.00m
- Incorporated2002
- Employees17.15k
- LocationLonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
- Phone+41 613168111
- Fax+41 613169111
- Websitehttps://www.lonza.com/
More ▼
Mergers & acquisitions
| Acquired company | LONN:SWX since announced | Transaction value |
|---|---|---|
| Codiak BioSciences Inc-Exosomes Manufacturing Facility,Lexington,MA | -26.02% | -- |
Data delayed at least 15 minutes, as of Aug 08 2022 12:17 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qiagen NV | 2.17bn | 494.49m | 10.88bn | 6.00k | 22.25 | 3.44 | 15.67 | 5.00 | 2.19 | 2.19 | 9.61 | 14.16 | 0.3749 | 2.42 | 6.45 | 368,421.50 | 8.53 | 3.69 | 9.71 | 4.28 | 64.44 | 65.54 | 22.75 | 11.68 | 1.89 | 181.36 | 0.3709 | -- | 20.39 | 10.97 | 42.71 | 44.84 | 17.07 | -- |
| Vifor Pharma AG | 1.75bn | 146.60m | 11.14bn | 2.30k | 76.11 | 3.19 | 23.68 | 6.35 | 2.25 | 2.22 | 26.98 | 53.78 | 0.3403 | 1.96 | 3.78 | 762,695.60 | 5.15 | 4.77 | 6.75 | 6.30 | 61.70 | 59.81 | 15.13 | 13.94 | 1.56 | -- | 0.132 | 102.79 | 2.85 | 8.49 | 5.70 | -0.0681 | -2.52 | 0.00 |
| Croda International Plc | 2.42bn | 825.02m | 11.48bn | 6.14k | 13.94 | 4.19 | 11.86 | 4.75 | 5.08 | 5.08 | 14.89 | 16.91 | 0.5686 | 2.71 | 4.97 | 339,511.00 | 19.52 | 11.17 | 22.63 | 13.16 | 48.22 | 43.71 | 34.33 | 16.39 | 2.25 | 24.36 | 0.3202 | 61.78 | 35.91 | 8.73 | 59.13 | 10.28 | 8.53 | 5.70 |
| BioMerieux SA | 3.30bn | 588.41m | 12.48bn | 13.08k | 21.06 | 4.04 | 15.13 | 3.78 | 5.06 | 5.06 | 28.42 | 26.40 | 0.7903 | 2.40 | 5.68 | 258,198.20 | 14.02 | 9.78 | 18.25 | 13.13 | 58.16 | 55.47 | 17.74 | 12.69 | 1.64 | 67.03 | 0.1272 | 14.14 | 8.27 | 9.93 | 48.64 | 27.40 | 4.48 | 20.59 |
| UCB SA | 5.80bn | 868.28m | 14.04bn | 8.56k | 16.16 | 1.57 | 10.94 | 2.42 | 4.56 | 4.56 | 30.47 | 46.94 | 0.4037 | 1.82 | 4.79 | 691,975.30 | 6.05 | 7.39 | 7.38 | 9.30 | 73.09 | 74.34 | 14.99 | 16.73 | 0.828 | 36.69 | 0.2528 | 28.56 | 8.04 | 6.85 | 44.13 | 14.21 | 29.00 | 2.48 |
| Eurofins Scientific SE | 6.71bn | 806.31m | 14.16bn | 61.00k | 18.25 | 3.08 | 10.14 | 2.11 | 4.12 | 3.21 | 34.27 | 24.42 | 0.7248 | 31.28 | 4.92 | 118,238.70 | 9.05 | 7.66 | 11.39 | 9.73 | 25.13 | 23.52 | 12.49 | 11.80 | 1.25 | 10.16 | 0.4124 | 16.22 | 23.51 | 21.50 | 50.07 | 39.88 | 21.07 | 37.97 |
| argenx SE | 120.65m | -872.42m | 19.53bn | 650.00 | -- | 6.84 | -- | 161.89 | -17.00 | -17.00 | 2.30 | 52.99 | 0.0388 | 0.0655 | 2.02 | 189,621.30 | -28.08 | -20.19 | -30.48 | -22.86 | 73.49 | -- | -723.09 | -191.43 | 10.56 | -8.94 | 0.0033 | -- | 1,105.73 | 98.16 | 32.90 | -- | 163.70 | -- |
| Lonza Group AG | 5.85bn | 909.00m | 41.72bn | 17.15k | 45.88 | 4.15 | 28.99 | 7.13 | 12.21 | 41.87 | 78.57 | 134.94 | 0.3667 | -- | -- | 360,648.70 | 5.72 | 5.00 | 7.01 | 6.14 | 38.69 | 39.82 | 15.59 | 13.97 | -- | 12.82 | 0.1924 | 31.40 | 19.99 | 5.53 | -7.67 | 17.49 | 29.66 | 3.33 |
| GSK plc | 37.98bn | 4.56bn | 78.69bn | 90.10k | 15.17 | 3.31 | 9.04 | 2.07 | 1.10 | 1.29 | 9.00 | 5.03 | 0.3941 | 2.06 | 4.90 | 363,201.50 | 5.80 | 6.96 | 10.20 | 11.61 | 65.40 | 68.48 | 14.71 | 14.68 | 1.31 | 10.40 | 0.4941 | 94.85 | 0.044 | 4.11 | -23.73 | 36.90 | 4.50 | -4.36 |
| Sanofi SA | 41.15bn | 6.49bn | 120.98bn | 95.44k | 18.50 | 1.72 | 14.78 | 2.94 | 5.27 | 5.27 | 33.50 | 56.67 | 0.3591 | 1.38 | 5.73 | 440,466.50 | 5.68 | 5.19 | 6.91 | 6.23 | 69.45 | 68.06 | 15.82 | 15.36 | 0.861 | 32.43 | 0.2311 | 66.94 | 4.83 | 2.46 | -49.38 | 7.20 | -0.387 | 2.28 |
| Novo Nordisk A/S | 20.68bn | 6.65bn | 173.27bn | 50.82k | 34.30 | 22.81 | 23.30 | 8.38 | 22.04 | 22.04 | 68.54 | 33.15 | 0.8342 | 1.25 | 4.70 | 3,290,321.00 | 26.81 | 32.65 | 51.95 | 63.12 | 83.92 | 83.79 | 32.14 | 33.52 | 0.7412 | 19.08 | 0.2546 | 50.18 | 10.91 | 4.72 | 13.33 | 4.72 | -2.23 | 6.47 |
| AstraZeneca plc | 42.34bn | -1.20bn | 196.79bn | 83.10k | -- | 5.70 | 32.00 | 4.65 | -0.7043 | -0.7043 | 23.66 | 19.21 | 0.5174 | 2.02 | 5.77 | 439,018.10 | -1.47 | 2.62 | -1.98 | 3.66 | 74.85 | 78.90 | -2.84 | 6.61 | 0.6737 | 5.85 | 0.451 | 196.26 | 40.58 | 10.22 | -96.50 | -49.76 | -1.01 | 1.03 |
Data as of Aug 08 2022. Currency figures normalised to Lonza Group AG's reporting currency: Swiss Franc CHF
19.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Investment Management (UK) Ltd.as of 31 Jul 2022 | 2.39m | 3.21% |
| The Vanguard Group, Inc.as of 08 Jul 2022 | 1.92m | 2.58% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 1.78m | 2.39% |
| Fidelity Management & Research Co. LLCas of 31 May 2022 | 1.69m | 2.27% |
| UBS Asset Management Switzerland AGas of 05 Jul 2022 | 1.41m | 1.90% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2022 | 1.29m | 1.73% |
| BlackRock Fund Advisorsas of 07 Jul 2022 | 1.19m | 1.60% |
| WCM Investment Management LLCas of 31 May 2022 | 957.63k | 1.29% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Jul 2022 | 835.34k | 1.12% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Mar 2022 | 767.22k | 1.03% |
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
